At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 32 enrolled
Drug / intervention
CBDdrug
Likely dose
CBD 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Dose Controlled Diabetic Neuropathic Pain Study Using Non-Intoxicating Cannabidiol in a Rapidly Dissolvable Sublingual Tablet
In Brief
A Phase 2 clinical trial evaluating CBD for Diabetic Neuropathies. Completed, enrolled 32 participants across 1 site.
Detailed Summary
Use of Cannabidiol for the treatment of Diabetic Neuropathic Pain.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetic Neuropathies
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedSep 2019
Enrollment StartSep 2019
Primary CompletionNov 2019
Study CompletionDec 2019
TodayJul 2026
First PostedSep 13, 2019
Enrollment StartSep 30, 2019
Primary CompletionNov 22, 2019
Study CompletionDec 1, 2019
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 6.8 years ago
Interventions
CBDdrug
A water-soluble sublingual tablet containing 20 mg of cannabidiol (CBD) and 0.1 mg of a proprietary blend of terpenes.